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Unplanned 30-Day Encounters After Ureterorenoscopy
for Urolithiasis
Kefu Du, MD,1 Robert S. Wang, MD,2 Joel Vetter, MS,1 Alethea G. Paradis, BA, MTS,1
Robert S. Figenshau, MD,1 Ramakrishna Venkatesh, MD,1 and Alana C. Desai, MD1
Abstract
Objective: To identify avoidable predictors of postureteroscopy (URS) unplanned encounters and to minimize
30-day encounters.
Materials and Methods: We performed retrospective chart review and telephone surveys on patients who
underwent URS for urolithiasis between January and June 2016. Univariate and multivariable analyses eval-
uated for potential predictors of unplanned encounters.
Results: Of 157 patients, there were 44 (28.0%) unplanned patient-initiated clinical phone calls, 23 (14.6%)
emergency department (ED) visits, and 8 (5.1%) readmissions, with pain being the most common complaint
during the encounters. Factors associated with a higher rate of phone calls include first-time stone procedure
(36.6% vs 20.9%, p = 0.029), outpatient status (30.3% vs 0%, p = 0.021), intraoperative stent placement (31.2%
vs 0%, p = 0.006), and stent removal at home (58.8% vs 28.8%, p = 0.014). Factors associated with increased
rate of ED visits were first-time stone procedure (22.5% vs 8.1%, p = 0.011) and ureteral access sheath (UAS)
usage (29.6% vs 11.8%, p = 0.018). Factors associated with a higher rate of readmissions were lower body mass
index (23.9 vs 29.7, p = 0.013), bilateral procedure (20.0% vs 2.9%, p = 0.010), and UAS usage (14.8% vs 3.1%,
p = 0.032). Stone burden, operative time, Charlson comorbidity index, and preoperative urinary tract infection
were not significantly associated with postoperative encounters.
Conclusions: Pain, first-time stone treatment, presence of a ureteral stent, outpatient status, bilateral procedures,
and UAS usage were common reasons for postoperative encounters after URS. Appropriate perioperative
patient education and counseling and adequate pain management may minimize these encounters and improve
treatment quality and patient satisfaction.
Keywords: renal stone, stents, ureteral stones, ureteroscopy, ureteroscopy instrumentation
Introduction
Nephrolithiasis is increasing in incidence, affectingapproximately 1 in 11 people in the United States during
their lifetime.1 With improvements in the optics and endo-
scope design, ureteroscopy (URS) is an increasingly popular
treatment modality for urolithiasis.2,3 Despite being a com-
mon ambulatory procedure, URS generates a relatively high
rate of postprocedural events such as telephone calls, emer-
gency department (ED) visits, and readmissions.4–7 These
events can negatively affect patients’ quality of life and sat-
isfaction and add to the cost of healthcare. The Centers for
Medicare and Medicaid Services and Hospital Quality Alli-
ance now recommend public reporting of 30-day readmission
or revisit rates as one of the quality-of-healthcare outcome
measures.8 There is sparse information on hospital revisits
after ureteroscopic stone treatment in the published litera-
ture.4 In this study, we evaluate risk factors for unplanned
encounters within 30 days after URS for urolithiasis.
Materials and Methods
After approval by the internal review board, we retrospec-
tively reviewed the medical records of patients who underwent
URS for upper tract urolithiasis between January and June 2016
at a tertiary care university hospital and two satellite hospitals.
These patients were identified using Current Procedural Ter-
minology codes 52352, 52353, and 52356 from hospital billing
data. Both elective and urgent cases were included.
1Division of Urologic Surgery, Washington University School of Medicine, St. Louis, Missouri.
2Division of Urology, University of Michigan Medical School, Ann Arbor, Michigan.
Findings from this study were presented at the American Urologic Association national conference in Boston, MA, in 2017. Part of the
text was published in the conference proceeding from that meeting.
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Preoperative urine culture was routinely performed, and
patients with positive cultures were treated with a course of
culture-appropriate antibiotics. Otherwise, patients received
preoperative prophylactic antibiotics at the time of proce-
dure, according to the American Urological Association Best
Practice Statement for urologic surgery antimicrobial pro-
phylaxis. Use of ureteral access sheath (UAS) and placement
of stent with or without extraction string were surgeon and
case dependent. Patients were discharged home if they met
discharge criteria, including stable vital signs and adequate
pain control, or were admitted to the hospital for observation,
if deemed necessary. All URS procedures were performed on
an outpatient basis, defined as discharge within 23 hours of
surgery. Patients were managed in the inpatient setting if they
were already admitted for other reasons or were admitted
postoperatively due to concerns during recovery.
Patient demographics, urolithiasis history, stone character-
istics, operative details, and 30-day postoperative unplanned
events were collected. These events included patient-initiated
phone calls, ED visits, and readmissions. Clinically related
phone calls were included, while administrative phone calls
were excluded. To capture the most accurate ED and read-
mission rates, surveys inquiring about any unplanned hospital
visits outside of our healthcare system were delivered to all
patients via telephone or email in October 2016 and supple-
mented chart review data.
Fisher’s exact and Wilcoxon rank-sum tests were used for
qualitative and quantitative variables, respectively. Statistical
significance was defined as p < 0.05. We performed univariate
analysis to identify predictors for unplanned phone calls, ED
visits, and readmissions. A multivariable logistic regression
model was constructed for ED visits and patient phone calls.
Results
We reviewed 157 URS procedures that had complete 30-
day data during the study period. The response rate of the
surveys was 40.7% (64 of 157). Baseline demographics and
stone data, operative data, and perioperative management for
the cohort are summarized in Table 1. The three busiest URS
surgeons performed 66, 22, and 17 cases, respectively, while
the remaining 52 cases were performed by 11 different sur-
geons. No differences in rate of encounters were found
among the surgeons (data not shown). Of the 27 cases in
which UAS was used, 11 cases (40.7%) used 12/14 French
size, 7 cases were unspecified, and the remaining 9 cases
were spread out among various inner diameters of 9 French to
11 French. All cases with UAS use underwent ureteral
stenting. For the 16 patients who were not stented, all but 4
had stents placed before the procedure; none had UAS used
during the procedure; and 12 of the operative reports stated
reason for omission of stents as minimal trauma/manipula-
tion, or the ureter appeared patent. Median stent dwell time
was 13 days (range 2–347 days). Median hospital stay for
patient managed as inpatient was 2 days. There were 44
(28.0%) unplanned patient-initiated clinical phone calls, 23
(14.6%) ED visits, and 8 (5.1%) readmissions during the 30-
day postoperative period. Median times to event were 5 days
(range 0–21 days) for phone calls, 8 days (range 1–29 days)
for ED visits, and 3 days (range 1–29 days) for readmissions.
Most patients visited the ED only once, while two (8.7%)
patients had two ED visits after surgery.
The most common reasons for telephone calls were stent-
related pain (16 patients, 36.4%), medication-related issues/
questions (6 patients, 13.6%), and pain not specific to stent (4
patients, 9.1%). The most common chief complaints for ED
visits and readmissions were flank pain (9 patients, 39.1%/3
patients, 37.5%), hematuria (3 patients, 13.0%/1 patient,
12.5%), and fever (2 patients, 8.7%/1 patient, 12.5%). The
most common ED diagnoses were urinary tract infection
(UTI) (6 patients, 26.1%), flank pain (5 patients, 21.7%), and
sepsis (3 patients, 13.0%) (Table 2). Of the six patients with
UTI diagnosis, only one had positive urine culture with
Staphylococcus epidermidis. All three patients with sepsis
diagnosis had positive blood cultures with methicillin-
resistant S. epidermidis, coagulase-negative Staphylococcus,
or yeast, and their preoperative cultures correlated with the
blood cultures. Two of the septic patients had antibiotic
treatment preoperatively, while therapy for the third patient
was unknown. All patients with positive postoperative urine
cultures had calcium oxalate stones, and no struvite stones
were reported. All patients with ED diagnoses of UTI or
sepsis had been stented during the URS procedure. During
their ED visits, the majority of patients (14 patients, 60.9%)
received imaging evaluation, of which the most frequent
modalities were CT (9 patients, 64.3%), chest X-ray (3 pa-
tients, 21.4%), and ultrasonography (2 patients, 14.3%). Ten
patients (43%) received antibiotics, but none underwent
percutaneous nephrostomy tube or stent placement. One pa-
tient (4.3%) required intensive care unit admission for sepsis.
Factors associated with a higher rate of phone calls
included first-time stone procedure (36.6% vs 20.9%,
p = 0.029), outpatient status (30.3% vs 0%, p = 0.021), in-
traoperative stent placement (31.2% vs 0%, p = 0.006), ex-
traction string on stent (51.7% vs 24.3%, p = 0.006), and stent
removal at home (58.8% vs 28.8%, p = 0.014). Factors as-
sociated with increased rate of ED visits were first-time stone
procedure (22.5% vs 8.1%, p = 0.011) and UAS usage (29.6%
vs 11.8%, p = 0.018). Factors associated with a higher rate of
readmission were lower body mass index (BMI) (23.9 vs
29.7, p = 0.013), bilateral procedure (20.0% vs 2.9%,
p = 0.010), and UAS use (14.8% vs 3.1%, p = 0.032). Of the
16 patients who had no intraoperative stenting, none had an
unplanned phone call, ED visit, or readmission. Other factors,
such as stone burden, operative time, Charlson comorbidity
index, and history of preoperative UTI, were not significantly
associated with postoperative encounters (Tables 3–5). On
multivariable logistic regression analysis, first-time stone
procedure (odds ratio [OR] = 2.37, 95% confidence interval
[CI] 1.12–5.00, p = 0.024) and stent removal at home
(OR = 4.41, 95% CI 1.43–13.58, p = 0.010) remained signif-
icant predictors of postoperative phone calls, while first-time
stone procedure (OR = 3.65, 95% CI 1.34–9.91, p = 0.011)
and UAS use (OR = 3.87, 95% CI 1.32–11.33, p = 0.014) re-
mained significantly associated with ED visits (Table 6).
Readmission was omitted from multivariate logistic regres-
sion because low event rate precluded meaningful analysis.
Discussion
In this retrospective study of unplanned postoperative
encounters after URS for urolithiasis in a tertiary aca-
demic medical center, patient-initiated phone calls, ED visits,
and readmissions occurred at rates of 1 in 4, 7, and 20,















































respectively. Thus, a significant portion of patients required
additional evaluation and/or intervention, resulting in an in-
creased burden to medical resources that should be recog-
nized given the frequency of URS as treatment for stones.
These encounter rates are similar to previous reports, with
ED visits occurring at roughly 15% and readmission rates
around 4% to 5%.4–7 Consistent with literature, pain was the
most common presenting symptom in our cohort in all types
of encounters, highlighting the associated discomfort, despite
the minimally invasive nature of the operation.4–7,9 There-
fore, adequate pain management with appropriate quantity of
analgesic prescriptions should be part of routine postopera-
tive care. Unfortunately, our data did not include prescrip-
tion records to allow detailed analysis of pain medication
requirement.
As suggested by Morgan et al.,6 although few objective
complications following URS occur, there appears to be a
high level of patient anxiety, uncertainty, and discomfort
following stone surgery. Therefore, effective preoperative
counseling to establish realistic periprocedural expecta-
tions may play an important role in reducing the incidence
of these encounters.5,6 The association of a higher rate of
patient-initiated phone calls and ED visits with first-time
stone procedure may reflect these patients’ unfamiliarity with
the procedure, leading them to seek medical advice even
though reassurance or conservative management may suffice.
Table 1. Overview Characteristics for the Cohort
Variable n (%)















1 or 2 99 (63.1)























Endoscopic procedure within 30 days prior
No 107 (68.2)
Yes 50 (31.8)
Stent in place at time of procedure
No 69 (45.9)
Yes 88 (54.1)


































No stent/unknown 19 (12.1)




Stent dwell time (days),b median (range) 13 (2–347)
Stent removal location
Home 17 (10.8)
Office/operating room 111 (70.7)
No stent/unknown 29 (18.5)
aIn 27 cases with ureteral access sheath use.
bIn 129 cases with known stent duration.
ASA = American Society of Anesthesia; BMI = body mass index;
SD = standard deviation.















































Similarly, outpatient status may limit patients’ interaction
with medical professionals at the time of URS, possibly
reducing the amount of counseling received. Given that the
median time to phone calls and ED visits are 5 and 8 days,
respectively, perhaps a routine follow-up phone call by trained
urology staff on postoperative days 2 to 3 may eliminate a
portion of these patient-initiated encounters and improve pa-
tient satisfaction, at least for first-time stone formers.
In the study by Tan et al.,7 unplanned admissions were
associated with any previous admission related to stones,
history of psychiatric illness, and bilateral procedures. An-
other study reported a complication rate of 9.7% after bi-
lateral URS, with the most common complication being
pain requiring rehospitalization or ED visits.10 Similarly,
we found that readmissions were associated with bilateral
procedures.7 This association may be due to increased
ureteral manipulation, risk of bilateral ureteral injury, and
longer operative time.7 The small number (20 cases) of bi-
lateral URS in our study precludes meaningful subgroup
analysis. Until further studies are performed, the increased
risk of readmissions should be balanced against the benefit
of avoiding a second anesthesia afforded by bilateral URS.
Although not seen in our study, other reported factors influ-
encing postoperative encounters include younger age, hy-
pertension, asthma or chronic obstructive pulmonary disease,
two or more comorbidities, no ureteral stent or endoscopic
urologic procedure within the last 30 days before URS, any
previous admission related to stones, history of psychiatric
illness, lower surgeon experience, lower volume center, and
renal calculi.4–7,11
Table 2. Postprocedural Encounter Chief




Telephone call 44 (100)
Pain attributed to stent 16 (36.4)
Medication issues/questions 6 (13.6)
Pain not specific to stent 4 (9.1)
Stent questions
(string, stent removal, etc.)
4 (9.1)
Fever 3 (6.8)





ED visit/readmission 23 (100)/8 (100)
Flank pain 9 (39.1)/3 (37.5)
Hematuria 3 (13.0)/1 (12.5)
Fever 2 (8.7)/1 (12.5)
Other (chest pain, seizures,
altered mental status, etc.)
9 (39.1)/3 (37.5)
ED diagnosis 23 (100)







ED = emergency department; UTI = urinary tract infection.


















Age (years), mean (SD) 51.1 (16.9) 53.5 (13.0) 0.443 51.8 (15.4) 51.8 (18.7) 0.802 51.3 (15.2) 61.1 (24.4) 0.156
Sex 0.727 0.363 1.000
Female 73.2 26.8 87.8 12.2 95.1 4.9
Male 70.7 29.3 82.7 17.3 94.7 5.3
Race 0.577 0.345 0.075
Black 78.3 21.9 84.4 15.6 93.8 6.3
White 69.6 30.4 87.0 13.0 96.5 3.5
Other/unknown 80.0 2.0 70.0 30.0 80.0 20.0
BMI (kg/m2), mean (SD) 29.6 (8.1) 29 (7.1) 0.847 29.6 (8.1) 28.3 (6.2) 0.526 29.7 (7.9) 23.9 (4.2) 0.013
Charlson comorbidity index 0.794 0.676 0.323
0 71.8 28.2 85.9 14.1 96.5 3.5
1 64.7 35.3 82.4 17.6 100.0 0.0
2 79.2 20.8 91.7 8.3 91.7 8.3
>2 71.0 29.0 80.6 19.4 90.3 9.7
ASA class 0.538 0.303 0.226
1 or 2 73.4 26.3 87.9 12.1 97.0 3.0
3 or 4 69.1 30.9 81.8 18.2 92.7 7.3
First-time stone procedure 0.029 0.011 0.142
No 79.1 20.9 91.9 8.1 97.7 2.3
Yes 63.4 36.6 77.5 22.5 91.5 8.5
History of ureteral stent 0.129 0.220 0.438
No 68.5 31.5 82.9 17.1 93.7 6.3
Yes 80.4 19.6 91.3 8.7 97.8 2.2















































Postoperative infection was diagnosed in nearly 40% of
ED visits in our cohort. Due to the brief nature of ED visits,
these were presumed UTIs, and five of the six UTI diagnoses
were not confirmed by culture. As such, culture-confirmed
infection only occurred in 4 of 157 patients (2.5%). Never-
theless, these patients account for 17.4% of patients pre-
senting to the ED, with three of four developing sepsis,
indicating the severity of the complication. Some risk factors
for postoperative infections after URS reported in the liter-
ature include preoperative stenting, longer operative time,
and positive stone culture.12,13 Blackmur et al.14 found that a
positive preoperative urine culture increased the odds of
postoperative urosepsis despite appropriate preoperative an-
tibiotic therapy. Our experience corroborates this finding,
where two of three patients who experienced sepsis postop-
eratively had positive preoperative urine culture and were
treated with a course of antibiotics preoperatively. While the
use of oral antibiotic prophylaxis is sufficient to prevent
symptomatic UTIs at the time of stent removal in patients after
uncomplicated ureteroscopic stone treatment, more intensive
antibiotic prophylaxis and careful monitoring may benefit
higher risk patients.14,15 Interestingly, compliance with the



















Case type 0.285 1.000 0.417
Elective 70.7 29.3 85.0 15.0 95.2 4.8
Urgent 90.0 10.0 90.0 10.0 90.0 10.0
Postoperative status 0.021 1.000 0.479
Outpatient/observation 69.7 30.3 84.8 15.2 95.2 4.8
Inpatient 100.0 0.0 91.7 8.3 91.7 8.3
Preoperative urine culture 0.793 1.000 0.216
No growth/insignificant
growth
72.2 27.8 87.6 12.4 96.9 3.1
Positive 76.2 23.8 90.5 9.5 90.5 9.5
Contaminated — — — — — —





No 66.3 33.7 87.4 12.6 95.8 4.2
Yes 82.5 17.5 82.5 17.5 92.5 7.5
Unknown — — — — — —
Endoscopic procedure
within 30 days prior
0.260 0.417 1.000
No 74.8 25.2 86.9 13.1 94.4 5.6
Yes 66.0 34.0 82.0 18.0 96.0 4.0
Stent in place at time
of procedure
0.552 1.000 0.731
No 69.6 30.4 85.5 14.5 94.2 5.8
Yes 73.9 26.1 85.2 14.8 95.5 4.5
Operative time (minutes) 0.515 0.768 0.728
Mean (SD) 62.5 (41.6) 60.4 (26.9) 62.0 (39.0) 61.4 (32.4) 62.1 (38.3) 57.8 (33.1)
No. of stones 0.803 1.000 1.000
1 70.0 30.0 85.0 15.0 95.0 5.0
2 75.8 24.2 84.8 15.2 93.9 6.1
‡2 68.8 31.3 87.5 12.5 96.9 3.1
Unknown — — — — — —
Laterality 1.000 0.178 0.010
Unilateral 71.5 28.5 86.9 13.1 97.1 2.9
Bilateral 75.0 25.0 75.0 25.0 80.0 20.0
Type of ureteroscope 0.050 0.147 0.574
Both 85.2 14.8 92.6 7.4 92.6 7.4
Flexible 63.6 36.4 81.8 18.2 93.2 6.8
Semirigid 80.8 19.2 96.2 3.8 100.0 0.0
Unknown — — — — — —
Ureteral access sheath 0.490 0.018 0.032
No 73.2 26.8 88.2 11.8 96.9 3.1
Yes 66.7 33.3 70.4 29.6 85.2 14.8
Unknown — — — — — —















































American Urological Association Best Practice Statement
on antibiotic prophylaxis has been associated with un-
planned hospital return for infection.12 In a study by Moses
et al.,12 postoperative cultures often showed organisms not
covered by the best practice statement regimens or organ-
isms not present on initial preoperative culture, such as
gram-positive organisms or common skin pathogens. The
authors suggested the potential benefit of providing both
gram-negative and gram-positive perioperative antibiotic
coverage to reduce the risk of infection.
Intriguingly, lower BMI was a risk factor for readmission
within 30 days. A phenomenon called ‘‘obesity paradox’’ has
been documented in general surgery, where overweight (BMI
25.1–30) and moderately obese (BMI 30.1–35) patients un-
dergoing nonbariatric general surgery have a significantly
lower risk of death than normal weight patients.16 A proposed
mechanism for this paradox includes sufficient nutritional
reserve and a more adaptive inflammatory response due to a
chronic low-grade inflammation in the obese state. Whether
the protective effect of mild to moderate obesity is present in
URS remains to be investigated.
UAS facilitates URS by improving visualization and
simplifying ureteral reentry, and despite mixed data on the
influence of UAS on stone-free rate, its ability to reduce renal
pelvic pressure during URS is an established benefit.17 While
one study reported a reduction of postoperative infectious
complications with UAS, this was not seen by others.14,18
Although a UAS was routinely used in their study, Morgan
et al.6 found that a larger UAS size was an independent
predictor for unplanned symptom-related encounters after
URS. Similarly, we observed that close to 30% of patients
who had UAS during their procedure visited the ED, with half
of them being readmitted. A potential explanation for the
higher hospital visit rate is that the cases in which UAS was
used were likely to be more complicated or had larger stone
burden. Another possible mechanism for increased pain in-
cludes induction of mechanical dilation by the UAS within
the ureter and upregulation of proinflammatory mediators
such as cyclooxygenase-2 and tumor necrosis factor-a,
causing ureteral edema and decreased ureteral blood flow,
leading to ureteral spasm or colic.17,19,20
Ureteral stent placement after UAS use has been advocated
as it decreases pain and the likelihood of undergoing CT
imaging in the ED.20,21 In our cohort, ureteral stenting was
associated with more phone calls, and questions or com-
plaints regarding stent-related symptoms constituted a large



















Stent placement 0.006 0.131 1.000
No 100.0 0.0 100.0 0.0 100.0 0.0
Yes 68.8 31.2 83.7 16.3 94.3 5.7
Stent size 0.763 0.698 0.585
£6F 69.4 30.6 84.7 15.3 94.4 5.6
‡7F 64.3 35.7 78.6 21.4 92.9 7.1
No stent/unknown — — — — — —
Extraction string on stent 0.006 0.410 0.662
No 75.7 24.3 85.2 14.8 94.8 5.2
Yes 48.3 51.7 79.3 20.7 93.1 6.9
Unknown — — — — — —
Stent removal location 0.014 0.305 1.000
Home 41.2 58.8 76.5 23.5 94.1 5.9
Office/operating room 71.2 28.8 85.6 14.4 94.6 5.4
No stent/unknown — — — — — —
Table 6. Multivariable Logistic Regression Analysis Modeling the Probability of One or More
Variable Odds ratio 95% Low 95% High p
Telephone calls
First stone procedure (yes vs no) 2.37 1.12 5.00 0.024
Stent removed at home (yes vs no/unknown) 4.41 1.43 13.58 0.010
Admission to hospital before operating room (yes vs no) 0.21 0.03 1.73 0.146
Sex: male vs female 0.86 0.40 1.86 0.701
Age (numeric): 10-year increase 1.18 0.91 1.51 0.207
ED visits
First stone procedure (yes vs no) 3.65 1.34 9.91 0.011
Use of ureteral sheath (yes vs no) 3.87 1.32 11.33 0.014
Sex: male vs female 1.46 0.57 3.79 0.432
Age (numeric): 10-year increase 0.92 0.68 1.26 0.610















































proportion of these calls. This observation is consistent with
multiple studies reporting hematuria and significant stent-
related irritative symptoms, including flank pain, dysuria, and
frequency.22,23 Although one study showed that unstented
patients were significantly more likely to have an unplanned
ED, hospital, or office visit, we did not find such a correla-
tion.23 In fact, none of the unstented patients in our cohort had
any phone calls, ED visits, or readmission, suggesting that
stentless URS is feasible in appropriately selected patients.
Stent-related symptoms appear to be significantly improved
by a-blockers.24,25 Other medical therapies include anti-
cholinergic medication with solifenacin, preoperative bel-
ladonna and opium suppository, and periureteral botulinum
toxin type A injection.26–28 Incorporation of certain medical
therapies to reduce stent discomfort should be considered
part of routine postoperative care after URS.
While we found a significant association between phone
calls with stent extraction string and stent removal at home,
others have reported no difference in stent-related quality of
life, pain at stent removal, rates of UTI, ED visits, or phone
calls.29 In fact, some patients may prefer stent removal using
the extraction string as they may feel less pain compared with
flexible cystoscopic stent removal.30 However, anxiety re-
garding self-removal of stent or concerns about the string
itself potentially led patients to seek medical advice in our
study. Thus, proper patient selection and clear instructions
may be helpful to reduce the number of phone calls, again
highlighting the need for adequate preoperative counseling to
manage patient expectations.
Other than its retrospective nature, our study is limited by
an absence of postoperative prescription history, which may
have informed us of medications that potentially prevent
certain encounters. Multiple surgeons performed the URS,
and no standardized operative technique or perioperative
patient care regimen was available (e.g., UAS use or stenting,
postoperative medications, or follow-up time frame), poten-
tially introducing confounders. We do not have data on un-
planned clinic visits since there is no clear distinction in
documentation between planned and unplanned clinic visits,
although these visits were rare in our anecdotal experience.
The duration of stenting was variable, with the median almost
2 weeks. The relatively long stent dwell time is likely due to
scheduling reasons, given that the vast majority of procedures
did not leave extraction strings and required stent removal in
the office or operating room. The true rate of ED visits and
readmissions may not be accurate due to visits outside of our
medical system. Although we attempted to minimize this error
by surveying patients at the time of study, the response rate of
the survey was only 40%. In addition, the relatively small
sample size limited multivariate statistical analysis. Finally,
the single-institution nature of the study conducted at a tertiary
academic center reduces the generalizability of our findings.
Conclusions
Postoperative encounters after ureteroscopic stone treat-
ment are common. Pain, first-time stone treatment, outpatient
status, bilateral procedures, presence of a ureteral stent, and
UAS usage were common reasons for these encounters. Ap-
propriate perioperative patient education and counseling and
adequate pain management may minimize these encounters
and improve treatment quality and patient satisfaction.
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